RE:RE:RE:RE:RE:RE:Dr. Kamat and Keytruda 1 Year CR in NMIBC TrialMacer wrote: fredgoodwinson wrote: Isn`t that what they call 'damning with faint praise'?
Thought he was supposed to be on our strength? LOL
This is about as positive as he can be given his position.
He must remain impaartial until there is data to support stronger positions.
True professional imo.
Me on the other hand, I can see PDT therapy used in place of BCG in the future if the results are supportive enough. It may take another trial to get to that point but that shouldn't discourage anybody here...lol
Macer
If the Company is able to duplicate the efficacy results observed in the Phase Ib NMIBC clinical study (67% Complete Response) at an interim analysis when approximately 20 to 25 patients have been enrolled and treated, Theralase plans to submit the interim analysis to the FDA to review the results, with a focus on obtaining accelerated approval for market commercialization of the Company's ACT treatment. that is what i thought we were told and.....
Theralase affiliated researches through peer reviewed publications and presentations presented in association with prominent scientific and clinical organizations support the safety, efficacy and robustness of Theralase's technology and the clear advantages of using TLD-1433 for treating NMIBC. The success of Theralase's Phase Ib NMIBC clinical study is a concrete example that Photo Dynamic Therapy ("PDT") metal based PDCs can become a viable option for treating various cancers. so lets drive south to the border and get it done ...Buffalo ,NY is very close .
happy thursday